发明名称 FUSION PROTEIN HAVING ENHANCED IN VIVO ERYTHROPOIETIN ACTIVITY
摘要 <p>Provided is a fusion protein comprising, at its carboxy terminal of human erythropoietin (EPO), a mutant having one to four amino acid substitutions in the carboxy terminal peptide (CTP) fragment of a human chorionic gonadotropin (HCG) β subunit, for increasing an in vivo half-life activity of EPO. The in vivo half-life can be greatly elongated while retaining the intrinsic activity of the EPO, without increasing the sugar chain content.</p>
申请公布号 WO2003048210(A1) 申请公布日期 2003.06.12
申请号 KR2002001493 申请日期 2002.08.06
申请人 发明人
分类号 主分类号
代理机构 代理人
主权项
地址